Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02970318 · MORE INFO

Limitations, agreements, and source contact

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL · Source last updated 2026-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Institution/Investigator will not publish or publicly present any study results without prior approval or prior to 12 months following completion of the study.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
Astrazeneca Clinical Trial
phone
1-888-292-9613
title
Study Director
Complete source fields
certain Agreement
other Details
Institution/Investigator will not publish or publicly present any study results without prior approval or prior to 12 months following completion of the study.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
Astrazeneca Clinical Trial
phone
1-888-292-9613
title
Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice